Radiopharm Theranostics Limited American Depositary Shares (RADX) - Total Liabilities
Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has total liabilities worth $37.81 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RADX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Radiopharm Theranostics Limited American Depositary Shares - Total Liabilities Trend (2022–2026)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Radiopharm Theranostics Limited American asset portfolio.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Khee San Bhd
KLSE:6203
|
Malaysia | RM6.09 Million |
|
Egeplast Ege Plastik Ticaret ve Sanayi AS
IS:EPLAS
|
Turkey | TL921.98 Million |
|
Caesarstone Ltd
NASDAQ:CSTE
|
USA | $259.23 Million |
|
Andalan Perkasa Abadi Tbk PT
JK:NASA
|
Indonesia | Rp27.32 Billion |
|
Radiant Innovation
TWO:3373
|
Taiwan | NT$72.50 Million |
|
BonTerra Resources Inc
V:BTR
|
Canada | CA$33.33 Million |
|
NORTH PEAK RESOURCES LTD.
F:B9TN
|
Germany | €1.56 Million |
|
Control Bionics Ltd
AU:CBL
|
Australia | AU$2.73 Million |
Liability Composition Analysis (2022–2026)
This chart breaks down Radiopharm Theranostics Limited American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See RADX net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Radiopharm Theranostics Limited American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Radiopharm Theranostics Limited American Depositary Shares (2022–2026)
The table below shows the annual total liabilities of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $37.81 Million | -13.29% |
| 2025-06-30 | $43.61 Million | -2.40% |
| 2024-06-30 | $44.68 Million | +52.14% |
| 2023-06-30 | $29.37 Million | +43.84% |
| 2022-06-30 | $20.42 Million | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more